Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis
Frontiers in Immunology · 26.01.2023 · 14
DOI: 10.3389/fimmu.2023.1069894 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Frontiers in Immunology, online erschienen am 26.01.2023. Verfasst von Mykhailo Buchynskyi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, Interferon-alpha. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
IFN-α intervention may block SARS-CoV-2 replication and normalize the deregulated innate immunity of COVID-19.
Aim
This meta-analysis aimed to investigate the efficacy of interferon IFN-α–containing regimens when treating patients with moderate-to-severe COVID-19. Material and methods PubMed, SCOPUS, and ClinicalTrials.gov were searched from inception to 15 January 2022. A systematic literature search was conducted by applying relevant terms for ‘COVID-19’ and ‘interferon-α’. The primary outcome enclosed the all-cause hospital mortality. The secondary outcomes constituted the length of hospital stay; hospital discharge; nucleic acid negative conversion.
Results
Eleven studies are enclosed in the meta-analysis. No significant difference in the all-cause mortality rate was found between the study and control groups (OR 0.2; 95% CI 0.05-1.2; I 2 = 96%). The implementation of interferon did not influence such outcomes as the length of hospital stay (OR 0.9; 95% CІ, 0.3-2.6; I 2 = 91%), nucleic acid negative conversion (OR 0.8; 95% CI, 0.04-17.2; I 2 = 94%). Nevertheless, IFN-α treatment resulted in a higher number of patients discharged from the hospital (OR 26.6; 95% CІ, 2.7-254.3; I 2 = 95%).
Conclusions
Thus, IFN-α does not benefit the survival of hospitalized COVID-19 patients but may increase the number of patients discharged from the hospital. Systematic review registration www.crd.york.ac.uk/prospero , identifier (CRD42022374589).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
- Department of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
- Department of Obstetrics and Gynecology, Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine.
- Biofilm Study Group, Department of Cell Regulatory Mechanisms, Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, Kiev, Ukraine.
- Endocrinology Department, Bogomolets National Medical University, Kyiv, Ukraine.
- Medical Laboratory CSD, Kyiv, Ukraine.
Zitieren
APA
Buchynskyi, M., Kamyshna, I., Lyubomirskaya, K., Moshynets, O., Kobyliak, N., Oksenych, V., & Kamyshnyi, A. (2023). Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1069894
Vancouver
Buchynskyi M, Kamyshna I, Lyubomirskaya K, Moshynets O, Kobyliak N, Oksenych V, et al. Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis. Frontiers in Immunology. 2023;14. doi:10.3389/fimmu.2023.1069894
BibTeX
@article{Buchynskyi2023,
author = {Buchynskyi, Mykhailo and Kamyshna, Iryna and Lyubomirskaya, Katerina and Moshynets, Olena and Kobyliak, Nazarii and Oksenych, Valentyn and Kamyshnyi, Aleksandr},
title = {Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis},
journal = {Frontiers in Immunology},
year = {2023},
volume = {14},
doi = {10.3389/fimmu.2023.1069894}
}
EUVIMED